Marlene Schülein

Marlene Schülein

Auto-generated profile, based on publicly available information

Marlene Schülein

Department of Medicine, Division of Rheumatology, Karolinska Institutet, and Center for Molecular Medicine (CMM), Karolinska University Hospital, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in Journal of Experimental Medicine
Verified
Journal Article
Open access
RRRamona Rica
Ramona Rica
MWMonika Waldherr
Monika Waldherr
EMEmi Miyakoda
Emi Miyakoda
AKAna Patricia Kutschat
Ana Patricia Kutschat
MSMarlene Schülein
Marlene Schülein
SSShinya Sakaguchi
Shinya Sakaguchi
CD8+ T cell exhaustion is a complex process involving the differentiation of persistently activated CD8+ T cells into functionally distinct cell subsets. Here, we investigated the role of the key epigenetic regulator histone deacetylase 1 (HDAC1) in the differentiation of exhausted T (Tex) cells during chronic viral infection. We uncovered that HDAC1 controls the generation and maintenance of effector-like CX3CR1+ Tex cells in a CD8+ T cell–intrinsic manner. Deletion of HDAC1 led to expansion of an alternative Tex subset characterized by high expression of T cell exhaustion markers, and this was accompanied by elevated viremia. HDAC1 bound to and facilitated an open chromatin state of effector-like signature gene loci in progenitor Tex cells, thereby priming cell fate specification toward the CX3CR1+ Tex subset. Our study uncovers a selective role for HDAC1 in CX3CR1+ Tex subset differentiation, which is essential for controlling viral load during chronic infection.

14 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMarlene Schuelein
Marlene Schuelein
MAMarcelo Afonso
Marcelo Afonso
MSMerel Sijbranda
Merel Sijbranda
DPDiego Velasquez Pulgarin
Diego Velasquez Pulgarin
ADAnatoly Dubnovitsky
Anatoly Dubnovitsky
BRBruno Raposo
Bruno Raposo
Objectives: Autoreactive T cells recognizing citrullinated antigens, although rare and difficult to study, are implicated in rheumatoid arthritis (RA). To allow functional studies and manipulation of such T cells, we have generated and characterized transgenic mice expressing a TCR cloned from an RA patient and reactive with a prominent target, citrullinated tenascin C (citTNC). Methods: A humanized TCR transgenic (hTCR-tg) mouse recognizing the citrullinated TNC22 (citTNC22) antigen in an HLA-DRB1*04:01 (HLA-DR4) restricted manner was developed by genetically engineering a chimeric TCR expressing murine constant domains and human V(D)J sequences. hTCR-tg mice were immune phenotyped in murine H-2 b and humanized HLA-DR4 backgrounds using full spectrum flow cytometry, cytokine ELISAs and fluorospot assays at steady-state and after antigen challenge. Additionally, we investigated the presence of antibodies to citTNC and arthritis following citTNC protein immunization. Results: Thymic selection of hTCR T cells differed between the two MHC-II alleles, with a normal CD4+ T cell development observed solely under HLA-DR4 restriction. The chimeric hTCR maintained its citTNC22 specificity in vitro and ex vivo, without cross-reactivity to native TNC22 or other citrullinated autoantigens. hTCR-tg CD4+ T cells responded to antigen challenge in vivo and provided support to IgG class-switch and antigen-specific antibody production. Moreover, protein immunized hTCR-tg mice developed arthritis after periarticular challenge with citTNC. Conclusions: hTCR-tg mice expressing an RA patient-derived autoreactive TCR develop functional antigen-specific and HLA-restricted CD4+ T cells. The combination of humanized HLA-DR4 and TNC22 mice will be a valuable tool in the development of antigen-specific therapies translatable to human disease.

11 September 2026 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
MSMarlene Schülein
Marlene Schülein
MAMarcelo Gomes Afonso
Marcelo Gomes Afonso
MSMerel Sijbranda
Merel Sijbranda
DPDiego Velasquez Pulgarin
Diego Velasquez Pulgarin
ADAnatoly Dubnovitsky
Anatoly Dubnovitsky
BRBruno Raposo
Bruno Raposo
Autoreactive T cells recognising citrullinated antigens, although rare and difficult to study, are implicated in rheumatoid arthritis (RA). To allow functional studies and manipulation of such T cells, we have generated and characterised transgenic mice expressing a T-cell receptor (TCR) cloned from a patient with RA and reactive with a prominent target, citrullinated tenascin C (citTNC). A humanised TCR transgenic (hTCR-tg) mouse recognising the citrullinated tenascin C22 (citTNC22) antigen in an HLA-DRB1*04:01 (HLA-DR4) restricted manner was developed by genetically engineering a chimeric TCR expressing murine constant domains and human V(D)J sequences. hTCR-tg mice were immune phenotyped in murine H-2b and humanised HLA-DR4 backgrounds using full-spectrum flow cytometry, cytokine enzyme-linked immunosorbent assays, and Fluorospot assays at steady state and after antigen challenge. Additionally, we investigated the presence of antibodies to citTNC and arthritis after citTNC protein immunisation. Thymic selection of hTCR T cells differed between the 2 major histocompatibility complex class II alleles, with normal CD4+ T-cell development observed solely under HLA-DR4 restriction. The chimeric hTCR maintained its citTNC22 specificity in vitro and ex vivo, without cross-reactivity to native TNC22 or other citrullinated autoantigens. hTCR-tg CD4+ T cells responded to antigen challenge in vivo and provided support to IgG class-switch and antigen-specific antibody production. Moreover, protein-immunised hTCR-tg mice developed arthritis after periarticular challenge with citTNC. hTCR-tg mice expressing an RA patient-derived autoreactive TCR develop functional antigen-specific and HLA-restricted CD4+ T cells. The combination of humanised HLA-DR4 and TNC22 mice will be a valuable tool in the development of antigen-specific therapies translatable to human disease.